EATG » WHO to review its interim guidance on the use of delamanid in the treatment of MDR-TB

WHO to review its interim guidance on the use of delamanid in the treatment of MDR-TB

WHO to review its interim guidance on the use of delamanid in the treatment of multidrug-resistant TB following the release of Phase III clinical trial results

The World Health Organization (WHO) has started preparations for a rapid review of its interim guidance on the use of delamanid in the treatment of patients with multidrug-resistant tuberculosis (MDR-TB). This follows the release of the phase III randomised control trial results by Otsuka Pharmaceutical at the 48th Union World Conference on Lung Health on 13 October.

Read the full announcement here.

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn
Source:
WHO
News categories: Tuberculosis, Guidelines